After lengthy discussions with regulators, Eli Lilly and Co has finally announced that , the U.S. product labels for its schizophrenia and bipolar depression drugs ‘Zyprexa’ and ‘Symbyaxto’ will have fresh warnings for weight increase, cholesterol and high blood glucose.

In a statement, the company said that the cases of weight increase and metabolic changes have been reported as unfavorable effects since Zyprexa’s approval in the United Sates in 1996 and Symbyax’s authorization in 2003.

The company’s statement added that the tags for both medicines have also contained the USFDA-assigned caution that suggests monitoring patients for high blood sugar levels and diabetes, since 2003.